Salt forms of a xanthine compound

US8865729B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Peter Sieger · Mittelbiberach, DE
• Waldemar Pfrengle · Seibersbach, DE

Key dates

• Filing date: Dec 22, 2009
• Grant date: Oct 21, 2014
• Expiry date: May 31, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C309/29
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to novel salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, a DPP-4 inhibitor and their use in pharmaceutical compositions useful in the treatment of type 2, diabetes, as well as their production.